Pacific Biosciences of California PACB Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's deferred revenue?
- Pacific Biosciences of California (PACB) reported deferred revenue of $16.33M in Q1 2026.
- How has Pacific Biosciences of California's deferred revenue changed year-over-year?
- Pacific Biosciences of California's deferred revenue increased by 7.1% year-over-year, from $15.24M to $16.33M.
- What is the long-term trend for Pacific Biosciences of California's deferred revenue?
- Over 5 years (2020 to 2025), Pacific Biosciences of California's deferred revenue has grown at a 12.8% compound annual growth rate (CAGR), from $8.72M to $15.94M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.